BioCentury
ARTICLE | Clinical News

Axys reports Phase II ulcerative colitis data

January 10, 2001 8:00 AM UTC

AXPH said that data from 53 evaluable patients (of a total of 56) in an open-label Phase II study of its APC 2059 tryptase inhibitor to treat ulcerative colitis showed that 51 percent of patients had ...